Press release
Investors who lost money with Akero Therapeutics, Inc. (NASDAQ: AKRO) should contact the Shareholders Foundation in connection with a pending Investigation
An investigation for investors in Akero Therapeutics, Inc. (NASDAQ: AKRO) shares over potential securities laws violations.
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Akero Therapeutics, Inc. (NASDAQ: AKRO) concerning whether a series of statements by Akero Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Francisco, CA based Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. Akero Therapeutics, Inc. (NASDAQ: AKRO
On October 10, 2023, Akero Therapeutics, Inc posted interim data from its Phase 2b SYMMETRY trial for its lead candidate efruxifermin ("EFX") in patients with liver disorder nonalcoholic steatohepatitis ("NASH"). Specifically, the Company stated that 22% (28mg) and 24% (50mg) of those on EFX and 14% on placebo indicated at least one stage improvement in fibrosis with no worsening of NASH at week 36, the trial's primary endpoint, but that these changes were not statistically significant. In addition, Akero Therapeutics, Inc added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events.
Shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) declined from $58.00 per share in June 2023, to as low as $11.25 per share on October 27, 2023.
Those who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors who lost money with Akero Therapeutics, Inc. (NASDAQ: AKRO) should contact the Shareholders Foundation in connection with a pending Investigation here
News-ID: 3456813 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with shares of Molina Healthcare, Inc. ( …
An investor, who purchased shares of Molina Healthcare, Inc. (NYSE: MOH), filed a lawsuit over alleged violations of Federal Securities Laws by Molina Healthcare, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Molina Healthcare, Inc. (NYSE: MOH) have certain options and for certain investors are short and strict deadlines running. Deadline: December 02, 2025. NYSE: MOH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CTO Realty Growth, Inc. (NYSE: CTO) Long Term Investor Alert: Investigation of p …
An investigation on behalf of current long-term investors in shares of CTO Realty Growth, Inc. (NYSE: CTO) concerning potential breaches of fiduciary duties by certain directors and officers of CTO Realty Growth, Inc. was announced.
Investors who are current long term investors in CTO Realty Growth, Inc. (NYSE: CTO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Lawsuit filed for Investors who lost money with shares of Marex Group plc (NASDA …
An investor, who purchased shares of Marex Group plc (NASDAQ: MRX), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Marex Group plc in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, have certain options…
LifeMD, Inc. (NASDAQ: LFMD) Investor Alert: Deadline in Lawsuit on October 27, 2 …
A deadline is coming up on October 27, 2025 in the lawsuit filed for certain investors of LifeMD, Inc. (NASDAQ: LFMD) over alleged securities laws violations by LifeMD, Inc.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and there are strict and short deadlines running. Deadline: October 27, 2025. LifeMD, Inc. (NASDAQ: LFMD) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Akero
Liver Fibrosis Market Set to Grow Substantially Through 2034, DelveInsight Proje …
DelveInsight's "Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The…
Investigation announced for Long-Term Investors in shares of Akero Therapeutics, …
An investigation was announced for current long-term investors in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) concerning potential breaches of fiduciary duties by certain directors of Akero Therapeutics, Inc.
Investors who are current long term investors in Akero Therapeutics, Inc. (NASDAQ: AKRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Liver Cirrhosis Market Key Trends, Leading Players, and Future Projections Secto …
The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
CoherentMI has released a statistical report titled "Liver Cirrhosis Market Recent Trends, In-depth Analysis, Size, and Forecast 2024-2031." This report offers a comprehensive overview of the competitive landscape, geographical segmentation,…
Deadline on June 25th coming up in Lawsuit for Investors who lost money with sha …
A deadline is coming up on June 25, 2024 in the lawsuit filed for certain investors of Akero Therapeutics, Inc. (NASDAQ: AKRO) over alleged securities laws violations by Akero Therapeutics, Inc. (NASDAQ: AKRO).
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and there are strict and short deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit filed for Investors who lost money with shares of Akero Therapeutics, In …
An investor, who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO), filed a lawsuit over alleged violations of Federal Securities Laws by Akero Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and for certain investors are short and strict deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Sales Mapping Software Market Growth Rate, Share, Overview, Future Scope, and Ke …
The Sales Mapping Software Market report encompasses an exhaustive qualitative and quantitative evaluation. The study includes growth trends, micro- and macro-economic indicators, regulations, and governmental policies. The Sales Mapping Software Market report analyses each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants determine the sub-segments be tapped into to achieve growth in the coming years.
Click Here For a Free…
